Voyager Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $15,336 | $13,365 | $5,200 | $6,473 |
Gross Profit | 15,336 | 13,365 | 5,200 | 6,473 |
EBITDA | -28,883 | -26,877 | -35,560 | -33,679 |
EBIT | -29,932 | -27,809 | -36,625 | -34,693 |
Net Income | -27,426 | -27,892 | -33,382 | -31,021 |
Net Change In Cash | 15,336 | 13,365 | 5,200 | 6,473 |
Free Cash Flow | -30,889 | -31,255 | -34,366 | -38,553 |
Cash | 65,300 | 45,125 | 43,940 | 74,755 |
Basic Shares | 58,691 | 58,803 | 58,666 | 58,349 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $40,374 | $80,001 | $250,008 | $40,907 |
Gross Profit | 40,374 | 80,001 | 157,836 | 40,907 |
EBITDA | -127,784 | -78,556 | 126,455 | -44,646 |
EBIT | -131,843 | -83,287 | 122,014 | -50,837 |
Net Income | -119,721 | -65,002 | 132,330 | -46,408 |
Net Change In Cash | 40,374 | 80,001 | 250,008 | 40,907 |
Cost of Revenue | -18,738 | |||
Free Cash Flow | -135,063 | -18,831 | 74,663 | -15,000 |
Cash | 65,300 | 71,367 | 68,802 | 98,959 |
Basic Shares | 58,691 | 57,667 | 44,569 | 38,356 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.47 |
2025-09-30 | -$0.47 |
2025-06-30 | -$0.57 |